Retrophin Inc (NASDAQ:RTRX) insider Noah L. Rosenberg sold 870 shares of the company’s stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $20.49, for a total value of $17,826.30. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Shares of RTRX stock opened at $20.69 on Friday. The stock’s 50-day simple moving average is $18.92 and its 200-day simple moving average is $16.28. The company has a debt-to-equity ratio of 0.92, a current ratio of 5.97 and a quick ratio of 5.88. Retrophin Inc has a fifty-two week low of $8.98 and a fifty-two week high of $21.92.

Retrophin (NASDAQ:RTRX) last announced its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.70. The business had revenue of $47.77 million for the quarter, compared to analyst estimates of $43.14 million. Retrophin had a negative return on equity of 43.15% and a negative net margin of 57.01%. As a group, equities analysts predict that Retrophin Inc will post -1.56 earnings per share for the current fiscal year.

Several hedge funds have recently made changes to their positions in the company. Bank of America Corp DE increased its holdings in shares of Retrophin by 9.3% in the fourth quarter. Bank of America Corp DE now owns 1,263,552 shares of the biopharmaceutical company’s stock valued at $17,942,000 after purchasing an additional 107,193 shares during the period. Nuveen Asset Management LLC increased its holdings in shares of Retrophin by 0.8% in the first quarter. Nuveen Asset Management LLC now owns 561,533 shares of the biopharmaceutical company’s stock valued at $8,193,000 after purchasing an additional 4,547 shares during the period. Assenagon Asset Management S.A. acquired a new position in shares of Retrophin in the first quarter valued at about $6,280,000. GW&K Investment Management LLC increased its holdings in shares of Retrophin by 82.9% in the first quarter. GW&K Investment Management LLC now owns 348,265 shares of the biopharmaceutical company’s stock valued at $5,081,000 after purchasing an additional 157,879 shares during the period. Finally, AXA increased its holdings in shares of Retrophin by 19.3% in the first quarter. AXA now owns 197,400 shares of the biopharmaceutical company’s stock valued at $2,880,000 after purchasing an additional 32,000 shares during the period.

RTRX has been the subject of a number of analyst reports. BTIG Research initiated coverage on Retrophin in a research note on Tuesday, June 16th. They set a “buy” rating and a $25.00 price objective for the company. ValuEngine cut Retrophin from a “strong-buy” rating to a “buy” rating in a research note on Friday, April 17th. Zacks Investment Research raised Retrophin from a “hold” rating to a “strong-buy” rating and set a $23.00 target price on the stock in a research report on Wednesday, July 15th. Canaccord Genuity reaffirmed a “buy” rating and set a $26.00 target price on shares of Retrophin in a research report on Tuesday, May 19th. Finally, BMO Capital Markets reduced their target price on Retrophin from $34.00 to $31.00 in a research report on Monday, July 13th. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $27.00.

Retrophin Company Profile

Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

Featured Article: Diversification in Investing

Insider Buying and Selling by Quarter for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.